BioSig Technologies to Partner with High Lantern Group
Leading global communication experts to lend support to BioSig’s growth strategy
Santa Monica, CA, April 26, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has appointed High Lantern Group (HLG) to assist in building a global stakeholder engagement strategy as the Company prepares for commercialization of its PURE EP(tm) System.
“Bioelectronic medicine – including the critical EP segment – represents the most exciting frontier in healthcare today, and BioSig intends to be at the forefront of innovation in this fast-growing market,” said Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. “At this stage of our development, we are pleased to partner with High Lantern Group, which has impressed us with their business and communications savvy and their skill at bringing together thought leaders to build alliances across multiple disciplines. We are excited to start this new chapter with the HLG team, and look forward to their valuable contributions.”
Headquartered in New York, and with key offices in Los Angeles, Washington, DC and Geneva Switzerland, High Lantern Group is a leading positioning, public affairs and communication firm with a deep understanding of the global healthcare arena from both a business and a policy perspective. HLG counts some of the world’s top healthcare and technology companies among its clients, and it has spearheaded the creation and success of several global coalitions, including the Global CEO Initiative on Alzheimer’s Disease and Global Coalition on Aging. The HLG team for BioSig Technologies will be led by Mario Ottiglio, HLG managing director based in Geneva, who has deep experience in the healthcare and pharmaceutical arena.
“Bioelectronic medicine has the potential to profoundly impact our lives in the years to come, revolutionizing how we manage patient outcomes. These new technologies will help society to address the increasing societal and economic burden due to our rapidly ageing society,” said Mr. Ottiglio. “We look forward to working together with BioSig in building awareness of the opportunities and galvanizing a vibrant industry ecosystem to accelerate innovation.”
About High Lantern Group
High Lantern Group (www.highlanterngroup.com) is one of the preeminent consulting firms in the field of strategic positioning and corporate reputation. The firm works at the intersection of business strategy and public policy, using the power of ideas to help clients build influence, enhance reputation and gain competitive advantage. Since its founding in 2009, High Lantern Group has served dozens of Fortune 1000 corporations, industry associations and non-profit organizations across multiple industries.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(tm) System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP(tm) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP(tm) System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
Released April 26, 2018
